This is the authors' abstract. We don't add key points for this paper.
MEFs and GI254023X-treated human cancer cell and tissue lysates, respectively. Additionally, the modified PrAMA simultaneously quantified with significant accuracy ADAM10sa and ADAM17sa in multiple human tumor specimens, and showed the essential characteristics of a robust high throughput multiplex assay that could be broadly used in biomarker studies. Selectively measuring specific enzyme activities, this new clinically applicable assay is potentially superior to the standard protein- and gene-expression assays that do not distinguish active and inactive enzyme forms.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yoneyama et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: